TY - JOUR
T1 - The Emulsified PFC Oxycyte® Improved Oxygen Content and Lung Injury Score in a Swine Model of Oleic Acid Lung Injury (OALI)
AU - Haque, Ashraful
AU - Scultetus, Anke H.
AU - Arnaud, Francoise
AU - Dickson, Leonora J.
AU - Chun, Steve
AU - McNamee, George
AU - Auker, Charles R.
AU - McCarron, Richard M.
AU - Mahon, Richard T.
N1 - Funding Information:
This work was funded by the U.S. Army Defense Health Program through work unit #60115HP.3720.001.A1016. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, nor the U.S. Government. This work was prepared as a part of official duties. Title 17 U.S.C. provides that ‘Copyright protection is not available for any work of the United States Government, and defined as work prepared by a military service member of employee of the U.S. Government as part of their official duties’. The authors would like to thank Tiffani Slaughter, USUHS, Dept. of Surgery (data entering) and Noemy Carballo, NMRC, NeuroTrauma Dept. (animal experiments) for their support in the execution of this study.
Publisher Copyright:
© 2016, Springer Science+Business Media New York (outside the USA).
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Purpose: Perfluorocarbons (PFCs) can transport 50 times more oxygen than human plasma. Their properties may be advantageous in preservation of tissue viability in oxygen-deprived states, such as in acute lung injury. We hypothesized that an intravenous dose of the PFC emulsion Oxycyte® would improve tissue oxygenation and thereby mitigate the effects of acute lung injury. Methods: Intravenous oleic acid (OA) was used to induce lung injury in anesthetized and instrumented Yorkshire swine assigned to three experimental groups: (1) PFC post-OA received Oxycyte® (5 ml/kg) 45 min after oleic acid-induced lung injury (OALI); (2) PFC pre-OA received Oxycyte® 45 min before OALI; and (3) Controls which received equivalent dose of normal saline. Animals were observed for 3 h after OALI began, and then euthanized. Results: The median survival times for PFC post-OA, PFC pre-OA, and control were 240, 87.5, and 240 min, respectively (p = 0.001). Mean arterial pressure and mean pulmonary arterial pressure were both higher in the PFC post-OA (p < 0.001 for both parameters). Oxygen content was significantly different between PFC post-OA and the control (p = 0.001). Histopathological grading of lung injury indicated that edema and congestion was significantly less severe in the PFC post-OA compared to control (p = 0.001). Conclusion: The intravenous PFC Oxycyte® improves blood oxygen content and lung histology when used as a treatment after OALI, while Oxycyte® used prior to OALI was associated with increased mortality. Further exploration in other injury models is indicated.
AB - Purpose: Perfluorocarbons (PFCs) can transport 50 times more oxygen than human plasma. Their properties may be advantageous in preservation of tissue viability in oxygen-deprived states, such as in acute lung injury. We hypothesized that an intravenous dose of the PFC emulsion Oxycyte® would improve tissue oxygenation and thereby mitigate the effects of acute lung injury. Methods: Intravenous oleic acid (OA) was used to induce lung injury in anesthetized and instrumented Yorkshire swine assigned to three experimental groups: (1) PFC post-OA received Oxycyte® (5 ml/kg) 45 min after oleic acid-induced lung injury (OALI); (2) PFC pre-OA received Oxycyte® 45 min before OALI; and (3) Controls which received equivalent dose of normal saline. Animals were observed for 3 h after OALI began, and then euthanized. Results: The median survival times for PFC post-OA, PFC pre-OA, and control were 240, 87.5, and 240 min, respectively (p = 0.001). Mean arterial pressure and mean pulmonary arterial pressure were both higher in the PFC post-OA (p < 0.001 for both parameters). Oxygen content was significantly different between PFC post-OA and the control (p = 0.001). Histopathological grading of lung injury indicated that edema and congestion was significantly less severe in the PFC post-OA compared to control (p = 0.001). Conclusion: The intravenous PFC Oxycyte® improves blood oxygen content and lung histology when used as a treatment after OALI, while Oxycyte® used prior to OALI was associated with increased mortality. Further exploration in other injury models is indicated.
KW - Acute respiratory distress syndrome (ARDS)
KW - Oleic acid (OA)
KW - Perfluorocarbon (PFC)
KW - Resuscitation and oleic acid-induced lung injury (OALI)
KW - Tissue oxygenation
UR - http://www.scopus.com/inward/record.url?scp=84990857119&partnerID=8YFLogxK
U2 - 10.1007/s00408-016-9941-9
DO - 10.1007/s00408-016-9941-9
M3 - Article
C2 - 27704259
AN - SCOPUS:84990857119
SN - 0341-2040
VL - 194
SP - 945
EP - 957
JO - Lung
JF - Lung
IS - 6
ER -